Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ De-recognition of operating lease liability on lease assignment / termination

De-recognition of operating lease liability on lease assignment / termination at other companies

Jefferies Financial Group logo
Jefferies Financial GroupJEF
$132.71M-11.9%
Schering-Plough logo
Schering-PloughSGP
$861.75K—
Ecolab logo
EcolabECL
$603.5M+0.8%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$7.6M—
Bloom Energy logo
Bloom EnergyBE
$20.18M—
Extra Space Storage logo
Extra Space StorageEXR
$10.53M—

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:DeRecognitionOfOperatingLeaseLiabilityOnLeaseAssignmentTermination.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's de-recognition of operating lease liability on lease assignment / termination.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's de-recognition of operating lease liability on lease assignment / termination?
Jazz Pharmaceuticals (JAZZ) reported de-recognition of operating lease liability on lease assignment / termination of $575K in Q4 2025.
How has Jazz Pharmaceuticals's de-recognition of operating lease liability on lease assignment / termination changed year-over-year?
Jazz Pharmaceuticals's de-recognition of operating lease liability on lease assignment / termination decreased by 89.2% year-over-year, from $5.32M to $575K.
What is the long-term trend for Jazz Pharmaceuticals's de-recognition of operating lease liability on lease assignment / termination?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's de-recognition of operating lease liability on lease assignment / termination has grown at a -57.1% compound annual growth rate (CAGR), from $68.06M to $2.3M.
What does de-recognition of operating lease liability on lease assignment / termination mean?
The value of lease debt removed due to lease termination.
How do you interpret de-recognition of operating lease liability on lease assignment / termination?
Reductions in lease liabilities through termination can improve the balance sheet, though they may involve exit costs.
How does de-recognition of operating lease liability on lease assignment / termination compare across companies?
Standardized accounting treatment for lease exits.